乳腺癌患者单核白细胞和血清中的胸苷激酶活性。
Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.
作者信息
McKenna P G, O'Neill K L, Abram W P, Hannigan B M
机构信息
Biomedical Sciences Research Centre, University of Ulster, Coleraine, Northern Ireland.
出版信息
Br J Cancer. 1988 Jun;57(6):619-22. doi: 10.1038/bjc.1988.141.
Abstract
Levels of the nucleotide pathway enzyme thymidine kinase (TK) were assayed in the mononuclear leukocytes and serum of 70 female patients with breast cancer and 98 male and 77 female non-cancer hospital patients. The total TK levels in both mononuclear leukocytes and serum from patients with breast cancer were significantly higher than in controls. The serum TK levels showed a significant correlation with cancer stage. No such correlation was observed with mononuclear leukocyte TK levels. Serum TK from 20 patients with breast cancer and 19 control patients was further assayed to ascertain the relative contributions of the thymidine kinase isozymes TK1 and TK2 to total TK levels. The increase in serum TK from breast cancer patients appears to be due to an increase in both TK1 and TK2 levels.
摘要
在70例女性乳腺癌患者以及98例男性和77例女性非癌症医院患者的单核白细胞和血清中检测了核苷酸途径酶胸苷激酶（TK）的水平。乳腺癌患者单核白细胞和血清中的总TK水平均显著高于对照组。血清TK水平与癌症分期显著相关。单核白细胞TK水平未观察到这种相关性。对20例乳腺癌患者和19例对照患者的血清TK进行了进一步检测，以确定胸苷激酶同工酶TK1和TK2对总TK水平的相对贡献。乳腺癌患者血清TK的升高似乎是由于TK1和TK2水平均升高所致。
相似文献
1
Thymidine kinase activities in mononuclear leukocytes and serum from breast cancer patients.乳腺癌患者单核白细胞和血清中的胸苷激酶活性。
Br J Cancer. 1988 Jun;57(6):619-22. doi: 10.1038/bjc.1988.141.
2
Can thymidine kinase levels in breast tumors predict disease recurrence?乳腺肿瘤中的胸苷激酶水平能否预测疾病复发？
J Natl Cancer Inst. 1992 Dec 2;84(23):1825-8. doi: 10.1093/jnci/84.23.1825.
3
A clinical evaluation of the TK 210 ELISA in sera from breast cancer patients demonstrates high sensitivity and specificity in all stages of disease.对乳腺癌患者血清进行的TK 210酶联免疫吸附测定临床评估表明，该测定在疾病各阶段均具有高敏感性和特异性。
Tumour Biol. 2016 Sep;37(9):11937-11945. doi: 10.1007/s13277-016-5024-z. Epub 2016 Apr 14.
4
The clinical significance of thymidine kinase 1 measurement in serum of breast cancer patients using anti-TK1 antibody.使用抗胸苷激酶1抗体检测乳腺癌患者血清中胸苷激酶1的临床意义。
Int J Biol Markers. 2000 Apr-Jun;15(2):139-46. doi: 10.1177/172460080001500203.
5
Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.血清胸苷激酶 1 活性作为接受新辅助帕博西尼治疗的早期乳腺癌患者细胞周期蛋白依赖性激酶 4/6 抑制的药效标志物。
Breast Cancer Res. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.
6
Selective inhibition of thymidine kinase isoenzymes by (E)-5-(2-bromovinyl)-2-deoxyuridine.（E）-5-（2-溴乙烯基）-2-脱氧尿苷对胸苷激酶同工酶的选择性抑制作用
Biochem Soc Trans. 1990 Apr;18(2):270. doi: 10.1042/bst0180270.
7
Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker.与血液系统恶性肿瘤患者和献血者相比，乳腺癌和前列腺癌患者血清胸苷激酶1（TK1）的比活性存在显著差异：血清TK1作为生物标志物的意义。
BMC Cancer. 2015 Feb 18;15:66. doi: 10.1186/s12885-015-1073-8.
8
Elevated serum and mononuclear leukocyte thymidine kinase activities in patients with cancer.癌症患者血清和单核白细胞胸苷激酶活性升高。
Ir Med J. 1987 Sep;80(9):264-5.
9
Breast tumour thymidine kinase levels and disease recurrence.乳腺肿瘤胸苷激酶水平与疾病复发
Med Lab Sci. 1992 Dec;49(4):244-7.
10
Thymidine kinase in breast cancer.乳腺癌中的胸苷激酶。
Br J Cancer. 1990 Oct;62(4):663-7. doi: 10.1038/bjc.1990.352.
引用本文的文献
1
Expression Profile of Thymidine Kinase Genes in Cervical Squamous Cell Carcinoma Confirmed by Various Detection Methods.多种检测方法证实的宫颈鳞状细胞癌中胸苷激酶基因的表达谱
World J Oncol. 2025 Feb;16(1):30-50. doi: 10.14740/wjon1962. Epub 2024 Dec 31.
2
Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.调节性 T 细胞与三阴性乳腺癌的肿瘤免疫微环境和免疫治疗反应有关。
Front Immunol. 2023 Sep 12;14:1263537. doi: 10.3389/fimmu.2023.1263537. eCollection 2023.
3
Dynamics of Serum Thymidine Kinase 1 at the First Cycle of Neoadjuvant Chemotherapy Predicts Outcome of Disease in Estrogen-Receptor-Positive Breast Cancer.新辅助化疗第一周期血清胸苷激酶1的动态变化可预测雌激素受体阳性乳腺癌的疾病转归
Cancers (Basel). 2021 Oct 29;13(21):5442. doi: 10.3390/cancers13215442.
4
Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial.评估 SWOG S0226 试验中接受一线内分泌治疗的激素受体阳性转移性乳腺癌患者的血清胸苷激酶 1。
Clin Cancer Res. 2021 Nov 15;27(22):6115-6123. doi: 10.1158/1078-0432.CCR-21-1562. Epub 2021 Sep 14.
5
Plasma thymidine kinase-1 activity predicts outcome in patients with hormone receptor positive and HER2 negative metastatic breast cancer treated with endocrine therapy.血浆胸苷激酶-1活性可预测接受内分泌治疗的激素受体阳性且人表皮生长因子受体2阴性转移性乳腺癌患者的预后。
Oncotarget. 2018 Mar 27;9(23):16389-16399. doi: 10.18632/oncotarget.24700.
6
Biomarker analysis and clinical relevance of TK1 on the cell membrane of Burkitt's lymphoma and acute lymphoblastic leukemia.伯基特淋巴瘤和急性淋巴细胞白血病细胞膜上TK1的生物标志物分析及其临床相关性
Onco Targets Ther. 2017 Sep 6;10:4355-4367. doi: 10.2147/OTT.S141239. eCollection 2017.
7
Thymidine Kinase Type 1 and C-Reactive Protein Concentrations in Dogs with Spontaneously Occurring Cancer.自发性患癌犬的1型胸苷激酶和C反应蛋白浓度
J Vet Intern Med. 2016 Jul;30(4):1159-66. doi: 10.1111/jvim.13954. Epub 2016 May 23.
8
Thymidine kinase 1 as a diagnostic tumor marker is of moderate value in cancer patients: A meta-analysis.胸苷激酶1作为一种诊断性肿瘤标志物在癌症患者中具有中等价值：一项荟萃分析。
Biomed Rep. 2013 Jul;1(4):629-637. doi: 10.3892/br.2013.114. Epub 2013 May 28.
9
Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.非霍奇金淋巴瘤患者肿瘤细胞及血清中的脱氧胸苷激酶
Br J Cancer. 1995 May;71(5):1099-105. doi: 10.1038/bjc.1995.213.
10
Comparison of plasma and tissue thymidine kinase activities.血浆与组织中胸苷激酶活性的比较。
Br J Cancer. 1989 Apr;59(4):660. doi: 10.1038/bjc.1989.135.
本文引用的文献
1
Thymidine kinase isoenzymes in human malignant lymphoma.人类恶性淋巴瘤中的胸苷激酶同工酶
Cancer Res. 1981 Feb;41(2):691-5.
2
Effect of 5-fluorouracil on the release of thymidine kinase from hepatoma cells in vitro.5-氟尿嘧啶对体外肝癌细胞胸苷激酶释放的影响。
Cancer Res. 1981 Jan;41(1):192-6.
3
Prognostic relevance of thymidine kinase isozymes in adult non-Hodgkin's lymphoma.胸苷激酶同工酶在成人非霍奇金淋巴瘤中的预后相关性
Blood. 1981 Nov;58(5):926-30.
4
Deoxycytidine and deoxythymidine kinase activities in plasma of mice and patients with neoplastic disease.小鼠和肿瘤疾病患者血浆中的脱氧胞苷激酶和脱氧胸苷激酶活性。
Cancer Res. 1982 Jun;42(6):2514-7.
5
The use of serum deoxythymidine kinase as a prognostic marker, and in the monitoring of patients with non-Hodgkin's lymphoma.血清脱氧胸苷激酶作为一种预后标志物的应用，以及在非霍奇金淋巴瘤患者监测中的应用。
Br J Cancer. 1983 Apr;47(4):487-95. doi: 10.1038/bjc.1983.78.
6
Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia.血清脱氧胸苷激酶可为慢性淋巴细胞白血病提供预后信息。
Cancer. 1984 Dec 1;54(11):2450-5. doi: 10.1002/1097-0142(19841201)54:11<2450::aid-cncr2820541123>3.0.co;2-r.
7
Serum thymidine kinase in acute leukaemia.急性白血病中的血清胸苷激酶
Br J Cancer. 1984 Apr;49(4):537-40. doi: 10.1038/bjc.1984.82.
8
Deoxythymidine-kinase in cerebrospinal fluid: a new potential "marker" for brain tumours.脑脊液中的脱氧胸苷激酶：一种用于脑肿瘤的新潜在“标志物”。
Acta Neurochir (Wien). 1984;73(1-2):1-12. doi: 10.1007/BF01401779.
9
10
Properties of thymidine kinase partially purified from human fetal and adult tissue.从人胎儿和成人组织中部分纯化的胸苷激酶的性质。
J Biol Chem. 1972 Mar 25;247(6):1930-5.
Zotero 插件